Literature DB >> 30203236

Novel 1,4-dihydropyridine induces apoptosis in human cancer cells through overexpression of Sirtuin1.

Debashri Manna1, Rajabrata Bhuyan1, Forid Saikh2,3, Somnath Ghosh2, Jayasri Basak4, Rita Ghosh5.   

Abstract

1,4-Dihydropyridines (1,4-DHPs) are important as a class of heterocyclic compounds that exhibit wide range of biological actions. Many of its derivatives are already characterized as medicinally important drugs and used worldwide. In this study, we have screened some novel Hantzsch 1,4-DHP compounds using both in silico (QSAR and Pharmacophore) and in vitro (cytotoxic screening). 1,4-DHP showed selective cytotoxicity against five human cancerous cell lines; A375, A549, HeLa, HepG2 and SH-SY5Y but limited effect towards normal skin keratinocyte (HaCaT), lung fibroblast (WL-38) and healthy peripheral blood mononuclear cells. In A375 and HepG2 cells, one of the 1,4-DHP derivative (DHP-8) was found to inhibit cell proliferation, and simultaneously increased the apoptotic population as well as mitochondrial membrane depolarization. Furthermore, the mitochondrial signal was triggered with the activation of cleaved Caspase9, Caspase3 and PARP. The treatment with DHP-8 also increased the expression level of SIRT1, subsequently decreasing the level of pAKTser473 and survivin. Reduced pAKTser473 expression led to decrease the phosphorylated inactive form of GSK3βser9 and as a result, proteasomal degradation of Mcl-1 occurred in both the cell lines. Here, we suggest that the apoptotic effect of DHP-8 in A375 and HepG2 cells was mediated by AKT and survivin pathways through SIRT1 activation. The involvement of DHP-8 in SIRT1 activation was further verified by co-treatment of nicotinamide with DHP-8 in both A375 and HepG2 cells. Overall, this study emphasizes the possible potential and therapeutic role of DHP-8 in skin and liver cancer.

Entities:  

Keywords:  1,4-DHP; AKT; Apoptosis; GSK3β; SIRT1; Survivin

Mesh:

Substances:

Year:  2018        PMID: 30203236     DOI: 10.1007/s10495-018-1483-6

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   4.677


  7 in total

1.  Probing the mechanism of SIRT1 activation by a 1,4-dihydropyridine.

Authors:  Debashri Manna; Rajabrata Bhuyan; Rita Ghosh
Journal:  J Mol Model       Date:  2018-11-17       Impact factor: 1.810

2.  Sirtuins: Developing Innovative Treatments for Aged-Related Memory Loss and Alzheimer's Disease.

Authors:  Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2018       Impact factor: 1.990

3.  9-phenyl acridine photosensitizes A375 cells to UVA radiation.

Authors:  Surajit Hansda; Gargi Ghosh; Rita Ghosh
Journal:  Heliyon       Date:  2020-09-03

4.  Immunomodulatory and antimicrobial non-mulberry Antheraea mylitta silk fibroin accelerates in vitro fibroblast repair and regeneration by protecting oxidative stress.

Authors:  Sohini Sen; Shaunak Ghosh; Sayantan De; Piyali Basak; Praveen Maurye; Nandan Kumar Jana; Tapan Kumar Mandal
Journal:  RSC Adv       Date:  2021-05-28       Impact factor: 3.361

5.  Discovery of new symmetrical and asymmetrical nitrile-containing 1,4-dihydropyridine derivatives as dual kinases and P-glycoprotein inhibitors: synthesis, in vitro assays, and in silico studies.

Authors:  Mohamed H Saad; Tarek F El-Moselhy; Nabaweya S El-Din; Ahmed B M Mehany; Amany Belal; Mohammed A S Abourehab; Haytham O Tawfik; Mervat H El-Hamamsy
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

6.  A375 melanoma cells are sensitized to cisplatin-induced toxicity by a synthetic nitro-flavone derivative 2-(4-Nitrophenyl)-4H-chromen-4-one through inhibition of PARP1.

Authors:  Anindita Mitra; Rita Ghosh
Journal:  Mol Biol Rep       Date:  2021-08-03       Impact factor: 2.316

Review 7.  Photosensitizing Medications and Skin Cancer: A Comprehensive Review.

Authors:  Elisabeth A George; Navya Baranwal; Jae H Kang; Abrar A Qureshi; Aaron M Drucker; Eunyoung Cho
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.